New Document top_band
 
Business Standard

Analysts' corner

Ranbaxy Laboratories & Havells India

Read more on:    Ranbaxy Laboratories | Havells India
Related News


Reco price/date: Rs 552/September 3
Current/target price: Rs 568.55/Rs 450
After the launch of Actos, Ranbaxy has given 14 per cent absolute returns, outperforming the market and the healthcare index by three per cent. However, the downward earnings revisions show the initial euphoria during the launch was not sustained. Also, except Lipitor, stocks have given negative returns in a six-month period. The trade recorded in a month was reversed in a two-quarter timeframe. Though the launch of Actos removes the overhang of the result of forfeiting exclusivities, analysts believe the competitive dynamics of the product launch would be tougher than initially estimated. They say this could lead to a downward estimate revision, as seen earlier. Maintain 'Sell'.

Antique Stock Broking


Reco price/date: Rs 550/September 3
Current/target price: Rs 555.25/Rs 680
The Havells India stock underperformed the Sensex by 6.0 per cent during the past three months. It is now trading at 12.1 times the 2013-14 estimated price/earnings ratio, which analysts believe is an attractive valuation. Analysts see steady growth in a tough operating environment, a strong balance sheet, improving free cash generation and a potential rise in the dividend payout as strong stock price drivers. JP Morgan thinks the recent guidance cut for Sylvania margins is priced in, and recent forex trends have become favourable. This could help alleviate concern on a further downside to Sylvania's margins. JP Morgan has raised its FY14 estimated earnings per share five per cent. Upgrade to 'Overweight' from 'Neutral'.

JP Morgan

Read more on:   
|

Read More

Fund managers divided on high beta preference

Riding high on the crest of the reforms wave, the markets touched their highest closing levels since July 2011 during the week under review ...

Quick Links

 

Market News

KPIT Technologies dips on weak Q1 results

KPIT Technologies plunged 7% to Rs 162 on the BSE after consolidated net profit dropped 17% to Rs 51 crore

Financial Technologies surges 25% in three days post stake sale in MCX

At 1250 hours, a combined 5 million shares changed hands and there are pending buy orders for 140,000 shares on BSE and NSE.

Mentha oil futures fall 0.87% on profit-booking

Oil for delivery in August lost 0.7%

Lead futures fall 0.26% on overseas trend, subdued demand

Market analysts said besides a weak trend in base metals at the LME, subdued demand put pressure on metal prices

Nickel down 0.4% on overseas trends, subdued demand

Metal for delivery in July also shed 0.38%

Back to Top